185 related articles for article (PubMed ID: 33501768)
1. Quantitative modeling predicts competitive advantages of a next generation anti-NKG2A monoclonal antibody over monalizumab for the treatment of cancer.
Spinosa P; Musial-Siwek M; Presler M; Betts A; Rosentrater E; Villali J; Wille L; Zhao Y; McCaughtry T; Subramanian K; Liu H
CPT Pharmacometrics Syst Pharmacol; 2021 Mar; 10(3):220-229. PubMed ID: 33501768
[TBL] [Abstract][Full Text] [Related]
2. Monalizumab: inhibiting the novel immune checkpoint NKG2A.
van Hall T; André P; Horowitz A; Ruan DF; Borst L; Zerbib R; Narni-Mancinelli E; van der Burg SH; Vivier E
J Immunother Cancer; 2019 Oct; 7(1):263. PubMed ID: 31623687
[TBL] [Abstract][Full Text] [Related]
3. Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells.
André P; Denis C; Soulas C; Bourbon-Caillet C; Lopez J; Arnoux T; Bléry M; Bonnafous C; Gauthier L; Morel A; Rossi B; Remark R; Breso V; Bonnet E; Habif G; Guia S; Lalanne AI; Hoffmann C; Lantz O; Fayette J; Boyer-Chammard A; Zerbib R; Dodion P; Ghadially H; Jure-Kunkel M; Morel Y; Herbst R; Narni-Mancinelli E; Cohen RB; Vivier E
Cell; 2018 Dec; 175(7):1731-1743.e13. PubMed ID: 30503213
[TBL] [Abstract][Full Text] [Related]
4. Population Pharmacokinetics of Monalizumab in Patients With Advanced Solid Tumors.
Hwang M; Fan C; Yue MS; Zhou D; Paturel C; Andre P; Cheng LY; Mitchell P; Kourtesis P; Ruscica D; Das M; Morsli N; Ren S; Gibbs M; Phipps A; Song X
J Clin Pharmacol; 2023 Jul; 63(7):817-829. PubMed ID: 36852723
[TBL] [Abstract][Full Text] [Related]
5. A target-mediated drug disposition population pharmacokinetic model of GC1118, a novel anti-EGFR antibody, in patients with solid tumors.
Chung TK; Lee HA; Park SI; Oh DY; Lee KW; Kim JW; Kim JH; Woo A; Lee SJ; Bang YJ; Lee H
Clin Transl Sci; 2021 May; 14(3):990-1001. PubMed ID: 33382918
[TBL] [Abstract][Full Text] [Related]
6. Model Informed Dosing Regimen and Phase I Results of the Anti-PD-1 Antibody Budigalimab (ABBV-181).
Powderly J; Spira A; Kondo S; Doi T; Luke JJ; Rasco D; Gao B; Tanner M; Cassier PA; Gazzah A; Italiano A; Tosi D; Afar DE; Parikh A; Engelhardt B; Englert S; Lambert SL; Kasichayanula S; Mensing S; Menon R; Vosganian G; Tolcher A
Clin Transl Sci; 2021 Jan; 14(1):277-287. PubMed ID: 32770720
[TBL] [Abstract][Full Text] [Related]
7. Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose-escalation phase 1 trial.
Patnaik A; Weiss GJ; Rasco DW; Blaydorn L; Mirabella A; Beeram M; Guo W; Lu S; Danaee H; McEachern K; Im E; Sachdev JC
Cancer Chemother Pharmacol; 2022 Jan; 89(1):93-103. PubMed ID: 34750637
[TBL] [Abstract][Full Text] [Related]
8. Monalizumab efficacy correlates with HLA-E surface expression and NK cell activity in head and neck squamous carcinoma cell lines.
Lee J; Keam B; Park HR; Park JE; Kim S; Kim M; Kim TM; Kim DW; Heo DS
J Cancer Res Clin Oncol; 2023 Aug; 149(9):5705-5715. PubMed ID: 36547689
[TBL] [Abstract][Full Text] [Related]
9. The NKG2A-HLA-E Axis as a Novel Checkpoint in the Tumor Microenvironment.
Borst L; van der Burg SH; van Hall T
Clin Cancer Res; 2020 Nov; 26(21):5549-5556. PubMed ID: 32409305
[TBL] [Abstract][Full Text] [Related]
10. Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study.
Shen L; Guo J; Zhang Q; Pan H; Yuan Y; Bai Y; Liu T; Zhou Q; Zhao J; Shu Y; Huang X; Wang S; Wang J; Zhou A; Ye D; Sun T; Gao Y; Yang S; Wang Z; Li J; Wu YL
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32561638
[TBL] [Abstract][Full Text] [Related]
11. Targeting NKG2A to elucidate natural killer cell ontogenesis and to develop novel immune-therapeutic strategies in cancer therapy.
Zaghi E; Calvi M; Marcenaro E; Mavilio D; Di Vito C
J Leukoc Biol; 2019 Jun; 105(6):1243-1251. PubMed ID: 30645023
[TBL] [Abstract][Full Text] [Related]
12. Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells.
Ruggeri L; Urbani E; André P; Mancusi A; Tosti A; Topini F; Bléry M; Animobono L; Romagné F; Wagtmann N; Velardi A
Haematologica; 2016 May; 101(5):626-33. PubMed ID: 26721894
[TBL] [Abstract][Full Text] [Related]
13. The NKG2A immune checkpoint - a new direction in cancer immunotherapy.
Creelan BC; Antonia SJ
Nat Rev Clin Oncol; 2019 May; 16(5):277-278. PubMed ID: 30824813
[No Abstract] [Full Text] [Related]
14. Pharmacokinetics and pharmacodynamics of MEDI0680, a fully human anti-PD-1 monoclonal antibody, in patients with advanced malignancies.
Song X; Khan AA; Zhou D; Elgeioushi N; Walcott F; Ren S; Gibbs M
Cancer Chemother Pharmacol; 2022 Mar; 89(3):373-382. PubMed ID: 35133489
[TBL] [Abstract][Full Text] [Related]
15. Dose-Ranging and Cohort-Expansion Study of Monalizumab (IPH2201) in Patients with Advanced Gynecologic Malignancies: A Trial of the Canadian Cancer Trials Group (CCTG): IND221.
Tinker AV; Hirte HW; Provencher D; Butler M; Ritter H; Tu D; Azim HA; Paralejas P; Grenier N; Hahn SA; Ramsahai J; Seymour L
Clin Cancer Res; 2019 Oct; 25(20):6052-6060. PubMed ID: 31308062
[TBL] [Abstract][Full Text] [Related]
16. [New frontiers in the fight against cancer].
Chiossone L; Vivier E
Biol Aujourdhui; 2018; 212(3-4):61-67. PubMed ID: 30973133
[TBL] [Abstract][Full Text] [Related]
17. Poor outcome with anti-programmed death-ligand 1 (PD-L1) antibody due to poor pharmacokinetic properties in PD-1/PD-L1 blockade-sensitive mouse models.
Kurino T; Matsuda R; Terui A; Suzuki H; Kokubo T; Uehara T; Arano Y; Hisaka A; Hatakeyama H
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32041818
[TBL] [Abstract][Full Text] [Related]
18. Preclinical to Clinical Translation of Antibody-Drug Conjugates Using PK/PD Modeling: a Retrospective Analysis of Inotuzumab Ozogamicin.
Betts AM; Haddish-Berhane N; Tolsma J; Jasper P; King LE; Sun Y; Chakrapani S; Shor B; Boni J; Johnson TR
AAPS J; 2016 Sep; 18(5):1101-1116. PubMed ID: 27198897
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of dosing strategy for pembrolizumab for oncology indications.
Freshwater T; Kondic A; Ahamadi M; Li CH; de Greef R; de Alwis D; Stone JA
J Immunother Cancer; 2017; 5():43. PubMed ID: 28515943
[TBL] [Abstract][Full Text] [Related]
20. Blocking the natural killer cell inhibitory receptor NKG2A increases activity of human natural killer cells and clears hepatitis B virus infection in mice.
Li F; Wei H; Wei H; Gao Y; Xu L; Yin W; Sun R; Tian Z
Gastroenterology; 2013 Feb; 144(2):392-401. PubMed ID: 23103614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
